Intravitreal use of triamcinolone acetonide: An experimental clinical procedure

Acta Ophthalmologica Scandinavica

Volumn 83, Issue 5, 2005, Pages 526-527

  Jonas, Jost B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE ACETONIDE;

CATARACTOGENESIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG COST; EDITORIAL; EYE DISEASE; HUMAN; INTRAOCULAR HYPERTENSION; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RESERVOIR; RETINA MACULA EDEMA; RETINA MACULA HOLE; RETINA VEIN OCCLUSION; SIDE EFFECT; TREATMENT OUTCOME; UVEITIS; VISION; VISUAL ACUITY; VITREOUS BODY;

GLUCOCORTICOIDS; HUMANS; INJECTIONS; RETINAL DISEASES; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 27144518520     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2005.00538.x     Document Type: Editorial

References (13)

1. Angunawela RI, Heatley CJ, Williamson TH, Spalton DJ, Graham EM, Antcliffe RJ & Stanford MR (2005): Intravitreal triamcinalone acetonide for refractory uvetic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand 83: 595-599.
2. D'Amico DJ, Goldberg MF & Hudson H et al. (2003): Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: 12-month clinical outcomes. Anecortave Acetate Clinical Study Group. Ophthalmology 110: 2372-2383.
3. Degenring R & Jonas JB (2004): Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 137: 1142-1143.
4. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W & Simpson JM (2005): Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 112: 139-143.
5. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M & Guyer DR (2004): Pegaptanib for neovascular age-related macular degeneration. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. N Engl J Med 351: 2805-2816.
6. Jonas JB, Degenring R, Kamppeter B, Kreissig I & Akkoyun I (2004): Duration of the effect of intravitreal triamcinolone acetonide as treatment of diffuse diabetic macular oedema. Am J Ophthalmol 138: 158-160.
7. Jonas JB, Degenring RF, Kreissig I, Akkoyun I & Kamppeter BA (2005b): Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 112: 593-598.
8. Jonas JB, Martus P, Degenring RF, Kreissig I & Akkoyun I (2005a): Predictive factors for visual acuity change after intravitreal triamcinolone for diabetic macular oedema. Arch Ophthalmol in press.
9. Krepler K, Ergun E, Sacu S, Richter-Müksch S, Wagner J, Stur M & Wedrich A (2005): Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand 83: 600-604.
10. Kytö JP, Angerman S, Lumiste E, Paloheimo M & Summanen PA (2005): Intravitreal triamcinolone acetonide as an adjuvant therapy to panretinal photocoagulation under intraconical anaesthesia for proliferative retinopathy with high-risk characteristics for severe visual loss and cystoid macular oedema in an adolescent patient with type 1 diabetes. Acta Ophthalmol Scand 83: 605-608.
11. Larsson J, Hvarfner C & Skarin A (2005): Intravitreal triamcinolone acetonide in two patients with refractory macular oedema in sarcoid uveitis. Acta Ophthalmol Scand 83: 618-619.
12. Machemer R, Sugita G & Tano Y (1979): Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 77: 171-180.
13. Ozdemir H, Karacorlu M & Karacorlu S (2005): Resolution of foveal pseudocyst after intravitreal triamcinolone acetonide. Acta Ophthalmol Scand 83: 619-620.